nature.com search

Loading Filters

Showing 1–18 of 18 results

Loading Filters

Reviews | 15 May 2014
'Toxgnostics': an unmet need in cancer medicine
- david.kerr@ndcls.ox.ac.uk
- David Church
- , Rachel Kerr
- , Enric Domingo
- , Dan Rosmarin
- , Claire Palles
- , Kevin Maskell
- , Ian Tomlinson
- & David Kerr
Nature Reviews Cancer 14 , 440–445

Rights & permissionsfor article 'Toxgnostics': an unmet need in cancer medicine . Opens in a new window.
Reviews | 1 July 2005
Adjuvant chemotherapy for stage II colorectal cancer: the time is right!
- David.Kerr@clinical-pharmacology.oxford.ac.uk
- Rachel Midgley
- & David J Kerr
Nature Clinical Practice Oncology 2 , 364–369

Rights & permissionsfor article Adjuvant chemotherapy for stage II colorectal cancer: the time is right! . Opens in a new window.
Reviews | 1 November 2004
Targeting angiogenesis in cancer: clinical development of bevacizumab
- david.kerr@clinpharm.ox.ac.uk
- David J Kerr
Nature Clinical Practice Oncology 1 , 39–43

Rights & permissionsfor article Targeting angiogenesis in cancer: clinical development of bevacizumab . Opens in a new window.
Reviews | 28 June 2016
Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach
- David Kerr is a consultant medical oncologist...
Nature Reviews Clinical Oncology 13 , 706–712

Rights & permissionsfor article Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach . Opens in a new window.
Reviews | 1 August 2003
Clinical development of gene therapy for colorectal cancer
- david.kerr@clinpharm.ox.ac.uk
- David Kerr
Nature Reviews Cancer 3 , 615–622

Rights & permissionsfor article Clinical development of gene therapy for colorectal cancer . Opens in a new window.
News & Views | 11 June 2013
Tailoring treatment and trials to prognosis
- david.kerr@ndcls.ox.ac.uk
- David J. Kerr
- & Yuankai Shi
Nature Reviews Clinical Oncology 10 , 429–430

Rights & permissionsfor article Tailoring treatment and trials to prognosis . Opens in a new window.
News & Views | 2 September 2014
EU data protection regulation—harming cancer research
- david.kerr@ndcls.ox.ac.uk
- David J. Kerr
Nature Reviews Clinical Oncology 11 , 563–564

Rights & permissionsfor article EU data protection regulation—harming cancer research . Opens in a new window.
Comments & Opinion | 1 April 2008
Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment
- David Kerr is Rhodes Professor of Clinical...
- David J Kerr
Nature Clinical Practice Oncology 5 , 250–251

Rights & permissionsfor article Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment . Opens in a new window.
News & Views | 1 September 2009
Cetuximab plus chemotherapy in patients with advanced NSCLC
- Dr. David Kerr is a Member of the...
- Kakil Ibrahim Rasul
- & David J. Kerr
Nature Reviews Clinical Oncology 6 , 499–500

Rights & permissionsfor article Cetuximab plus chemotherapy in patients with advanced NSCLC . Opens in a new window.
Comments & Opinion | 1 September 2006
Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?
- david.kerr@clinical-pharmacology.oxford.ac.uk
- David J Kerr
Nature Clinical Practice Oncology 3 , 480–481

Rights & permissionsfor article Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis? . Opens in a new window.
News & Views | 1 May 2012
Manufacturer sponsorship bias in economic analyses matters
- david.kerr@ndcls.ox.ac.uk
- David Kerr
- & Ahmed Elzawawy
Nature Reviews Clinical Oncology 9 , 309–310

Rights & permissionsfor article Manufacturer sponsorship bias in economic analyses matters . Opens in a new window.
Reviews | 20 January 2009
Evolution of nonsurgical therapy for colorectal cancer
- david.kerr@clinpharm.ox.ac.uk
Nature Clinical Practice Gastroenterology & Hepatology 6 , 108–120

Rights & permissionsfor article Evolution of nonsurgical therapy for colorectal cancer . Opens in a new window.
News & Views | 8 March 2011
Bevacizumab—has it reached its final resting place?
- david.kerr@clinpharm.ox.ac.uk
- David J. Kerr
- & Annie M. Young
Nature Reviews Clinical Oncology 8 , 195–196

Rights & permissionsfor article Bevacizumab—has it reached its final resting place? . Opens in a new window.
Comments & Opinion | 1 August 2006
A new model for cancer research in France
- David Kerr is Rhodes Professor of clinical...
- David Khayat
- & David Kerr
Nature Reviews Cancer 6 , 645–651

Rights & permissionsfor article A new model for cancer research in France . Opens in a new window.
Reviews | 11 March 2014
Building capacity for sustainable research programmes for cancer in Africa
- Dr. David Kerr has made sustained and internationally...
- Isaac Adewole
- , Damali N. Martin
- , Makeda J. Williams
- , Clement Adebamowo
- , Kishor Bhatia
- , Christine Berling
- , Corey Casper
- , Karima Elshamy
- , Ahmed Elzawawy
- , Rita T. Lawlor
- , Rosa Legood
- , Sam M. Mbulaiteye
- , Folakemi T. Odedina
- , Olufunmilayo I. Olopade
- , Christopher O. Olopade
- , Donald M. Parkin
- , Timothy R. Rebbeck
- , Hana Ross
- , Luiz A. Santini
- , Julie Torode
- , Edward L. Trimble
- , Christopher P. Wild
- , Annie M. Young
- & David J. Kerr
Nature Reviews Clinical Oncology 11 , 251–259

Rights & permissionsfor article Building capacity for sustainable research programmes for cancer in Africa . Opens in a new window.
Reviews | 23 September 2014
Clinical cancer research: the past, present and the future
- david.kerr@ndcls.ox.ac.uk
Nature Reviews Clinical Oncology 11 , 663–669

Rights & permissionsfor article Clinical cancer research: the past, present and the future . Opens in a new window.
Reviews | 23 August 2011
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
- David Kerr CBE MA MD DSc FRCP...
- Nicholas B. La Thangue
- & David J. Kerr
Nature Reviews Clinical Oncology 8 , 587–596

Rights & permissionsfor article Predictive biomarkers: a paradigm shift towards personalized cancer medicine . Opens in a new window.
Comments & Opinion | 1 May 2008
The challenge of cancer control in Africa
- David.Kerr@clinpharm.ox.ac.uk
- Rebecca J. Lingwood
- , Peter Boyle
- , Alan Milburn
- , Twalib Ngoma
- , John Arbuthnott
- , Ruth McCaffrey
- , Stewart H. Kerr
- & David J. Kerr
Nature Reviews Cancer 8 , 398–403

Rights & permissionsfor article The challenge of cancer control in Africa . Opens in a new window.

Refine your results by…

Filters

Filter By:

'Toxgnostics': an unmet need in cancer medicine

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Targeting angiogenesis in cancer: clinical development of bevacizumab

Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach

Clinical development of gene therapy for colorectal cancer

Tailoring treatment and trials to prognosis

EU data protection regulation—harming cancer research

Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment

Cetuximab plus chemotherapy in patients with advanced NSCLC

Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?

Manufacturer sponsorship bias in economic analyses matters

Evolution of nonsurgical therapy for colorectal cancer

Bevacizumab—has it reached its final resting place?

A new model for cancer research in France

Building capacity for sustainable research programmes for cancer in Africa

Clinical cancer research: the past, present and the future

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

The challenge of cancer control in Africa

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters